Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016', provides in depth analysis on Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics. The report provides comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview 8 Therapeutics Development 9 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development 9 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area 10 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication 11 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies 14 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development 20 Amgen Inc. 20 Array BioPharma Inc. 21 Astellas Pharma Inc. 22 CymaBay Therapeutics, Inc. 23 Daiichi Sankyo Company, Limited 24 F. Hoffmann-La Roche Ltd. 25 GlaxoSmithKline Plc 26 Hyundai Pharmaceutical Co., Ltd. 27 LG Life Science LTD. 28 Merck & Co., Inc. 29 Novartis AG 30 Sanwa Kagaku Kenkyusho Co., Ltd. 31 Taisho Pharmaceutical Holdings Co., Ltd. 32 Takeda Pharmaceutical Company Limited 33 Yuhan Corporation 34 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles 35 17-i - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ARRY-981 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AS-1669058 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 DA-1241 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 DS-8500 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 GSK-2041706 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 HD-0471042 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 HD-0471953 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 HOB-047 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 LC-34AD3 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 MBX-2982 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecule to Agonize GPR119 for Type II Diabetes - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecule to Agonize GPR119 for Undisclosed Indication - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecules to Agonize GPR119 for Metabolic Disorders - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecules to Agonize GPR119 for Type II Diabetes - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules to Agonize GPR119 Receptor for Type II Diabetes - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 YH-18420 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Projects 56 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products 58 Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Featured News & Press Releases 59 Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round 59 Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 59 Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Amgen Inc., H2 2016 20 Pipeline by Array BioPharma Inc., H2 2016 21 Pipeline by Astellas Pharma Inc., H2 2016 22 Pipeline by CymaBay Therapeutics, Inc., H2 2016 23 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 24 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25 Pipeline by GlaxoSmithKline Plc, H2 2016 26 Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 27 Pipeline by LG Life Science LTD., H2 2016 28 Pipeline by Merck & Co., Inc., H2 2016 29 Pipeline by Novartis AG, H2 2016 30 Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 31 Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 32 Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33 Pipeline by Yuhan Corporation, H2 2016 34 Dormant Projects, H2 2016 56 Dormant Projects (Contd..1), H2 2016 57 Discontinued Products, H2 2016 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
